Leerink Swann restated their outperform rating on shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) in a research note released on Tuesday. Leerink Swann currently has a $94.00 price target on the biopharmaceutical company’s stock, up from their previous price target of $85.00.

Analyst Recommendations for Ultragenyx Pharmaceutical (NASDAQ:RARE)

RARE has been the subject of a number of other reports. Jefferies Group set a $109.00 target price on Ultragenyx Pharmaceutical and gave the company a buy rating in a research note on Monday, September 12th. Credit Suisse Group AG reiterated a buy rating and set a $101.00 price objective on shares of Ultragenyx Pharmaceutical in a research report on Wednesday, September 14th. Wedbush reiterated an outperform rating and set a $92.00 price objective on shares of Ultragenyx Pharmaceutical in a research report on Tuesday, June 28th. Canaccord Genuity reiterated a buy rating and set a $120.00 price objective on shares of Ultragenyx Pharmaceutical in a research report on Thursday, June 16th. Finally, Piper Jaffray Cos. began coverage on Ultragenyx Pharmaceutical in a research report on Thursday, July 7th. They set an overweight rating and a $70.00 price objective for the company. Three investment analysts have rated the stock with a hold rating, fourteen have given a buy rating and one has assigned a strong buy rating to the company’s stock. The company has an average rating of Buy and an average price target of $97.89.

Ultragenyx Pharmaceutical (NASDAQ:RARE) traded down 0.62% during trading on Tuesday, reaching $75.48. The company’s stock had a trading volume of 159,578 shares. Ultragenyx Pharmaceutical has a 52 week low of $46.52 and a 52 week high of $117.12. The firm has a 50-day moving average price of $67.59 and a 200-day moving average price of $63.06. The firm’s market capitalization is $2.98 billion.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last issued its earnings results on Monday, August 8th. The biopharmaceutical company reported ($1.46) EPS for the quarter, missing the Zacks’ consensus estimate of ($1.44) by $0.02. During the same quarter in the prior year, the business posted ($0.83) earnings per share. On average, equities analysts anticipate that Ultragenyx Pharmaceutical will post ($5.96) EPS for the current fiscal year.

In other Ultragenyx Pharmaceutical news, insider Sunil Agarwal sold 649 shares of the business’s stock in a transaction on Thursday, July 21st. The shares were sold at an average price of $52.68, for a total transaction of $34,189.32. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, CEO Emil D. Kakkis sold 20,000 shares of the business’s stock in a transaction on Monday, August 15th. The shares were sold at an average price of $67.61, for a total transaction of $1,352,200.00. Following the sale, the chief executive officer now directly owns 493,244 shares in the company, valued at $33,348,226.84. The disclosure for this sale can be found here. 10.10% of the stock is owned by company insiders.

A number of hedge funds have recently made changes to their positions in RARE. Pacer Advisors Inc. purchased a new stake in shares of Ultragenyx Pharmaceutical during the second quarter valued at about $100,000. DIAM Co. Ltd. purchased a new stake in shares of Ultragenyx Pharmaceutical during the second quarter valued at about $177,000. Springbok Capital Management LLC purchased a new stake in shares of Ultragenyx Pharmaceutical during the first quarter valued at about $189,000. BlackRock Inc. increased its stake in shares of Ultragenyx Pharmaceutical by 58.5% in the second quarter. BlackRock Inc. now owns 3,973 shares of the biopharmaceutical company’s stock valued at $194,000 after buying an additional 1,467 shares during the period. Finally, Creative Planning increased its stake in shares of Ultragenyx Pharmaceutical by 16,700.0% in the second quarter. Creative Planning now owns 4,200 shares of the biopharmaceutical company’s stock valued at $205,000 after buying an additional 4,175 shares during the period. 93.06% of the stock is currently owned by institutional investors.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc is a clinical-stage biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of products for the treatment of genetic diseases. The Company is engaged in the identification, acquisition, development and commercialization of products for the treatment of rare and ultra-rare diseases segment.

5 Day Chart for NASDAQ:RARE

Receive News & Ratings for Ultragenyx Pharmaceutical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ultragenyx Pharmaceutical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.